Brokerages forecast that Myriad Genetics, Inc. (NASDAQ:MYGN) will report sales of $204.49 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Myriad Genetics’ earnings. The lowest sales estimate is $201.60 million and the highest is $209.06 million. Myriad Genetics posted sales of $190.20 million during the same quarter last year, which would indicate a positive year over year growth rate of 7.5%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, November 6th.

On average, analysts expect that Myriad Genetics will report full year sales of $904.34 million for the current fiscal year, with estimates ranging from $884.60 million to $936.10 million. For the next fiscal year, analysts forecast that the business will post sales of $971.20 million, with estimates ranging from $920.00 million to $1.03 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Myriad Genetics.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, August 21st. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.05. Myriad Genetics had a return on equity of 9.78% and a net margin of 17.69%. The firm had revenue of $200.90 million during the quarter, compared to analyst estimates of $195.93 million. During the same period last year, the firm posted $0.30 EPS. The business’s revenue was up .7% compared to the same quarter last year.

Several equities research analysts have recently issued reports on MYGN shares. ValuEngine lowered Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 21st. Morgan Stanley raised Myriad Genetics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $35.00 to $55.00 in a report on Wednesday, July 11th. Bank of America lifted their price objective on Myriad Genetics from $20.00 to $31.00 and gave the stock an “underperform” rating in a report on Monday, July 16th. BidaskClub lowered Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 21st. Finally, Piper Jaffray Companies lifted their price objective on Myriad Genetics to $38.00 and gave the stock a “neutral” rating in a report on Wednesday, August 22nd. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. Myriad Genetics currently has an average rating of “Hold” and an average target price of $41.10.

Shares of Myriad Genetics stock traded down $0.19 during trading hours on Wednesday, hitting $43.50. 969,537 shares of the company’s stock traded hands, compared to its average volume of 733,741. Myriad Genetics has a 12-month low of $27.23 and a 12-month high of $50.44. The firm has a market cap of $3.26 billion, a PE ratio of 36.25, a P/E/G ratio of 3.12 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.19 and a quick ratio of 2.86.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Robecosam AG grew its holdings in Myriad Genetics by 39.8% during the 2nd quarter. Robecosam AG now owns 4,193 shares of the company’s stock valued at $156,000 after buying an additional 1,193 shares in the last quarter. Piedmont Investment Advisors LLC grew its holdings in Myriad Genetics by 1.9% during the 2nd quarter. Piedmont Investment Advisors LLC now owns 70,179 shares of the company’s stock valued at $2,623,000 after buying an additional 1,285 shares in the last quarter. Vident Investment Advisory LLC grew its holdings in Myriad Genetics by 1.5% during the 2nd quarter. Vident Investment Advisory LLC now owns 86,231 shares of the company’s stock valued at $3,222,000 after buying an additional 1,293 shares in the last quarter. Amalgamated Bank grew its holdings in Myriad Genetics by 14.0% during the 2nd quarter. Amalgamated Bank now owns 10,611 shares of the company’s stock valued at $397,000 after buying an additional 1,302 shares in the last quarter. Finally, CWM LLC boosted its position in shares of Myriad Genetics by 0.6% during the 2nd quarter. CWM LLC now owns 282,289 shares of the company’s stock valued at $10,549,000 after acquiring an additional 1,650 shares during the last quarter.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Further Reading: How is an ETF different from a mutual fund?

Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.